|  Nederlands |  English |
 
 

08/11/2005: The Greatest Belgian

Dr. Paul Janssen: “The Greatest Belgian”?

We are firmly convinced that there are few Belgians who have meant as much for human health on this planet as
Dr. Paul Janssen. For hundreds of millions of patients the medicines he and his teams discovered continue to make the difference between life and death, pain and comfort, disease and health. This fact alone justifies his selection as “The Greatest Belgian”. Moreover, he was a versatile entrepreneur, who, with the Belgian Kempen region as his home base, built up a worldwide company that today is a major part of the third largest pharmaceutical company in the world, namely Johnson & Johnson. For several decades now Janssen Pharmaceutica has been one of the most important employers in the region and the biggest investor in R&D in Belgium.

Dr. Paul Janssen was not only a driven scientist; he was also deeply involved in the lot of all patients. Until the last day of his life he was searching for new medicines, especially for AIDS and other serious diseases that threaten humanity – “because that is the only thing I can do”, as he used to say with typical modesty.

An Outstandingly Successful Scientist
Dr. Paul Janssen (1926-2003) is generally recognized as one of the most successful investigators into new medicines of the twentieth century. This phenomenally driven and brilliant scientist, together with his teams, developed numerous innovative medicines effective in an extensive range of diseases and disease-related areas, among them pain control, psychiatry, gastroenterology, and various infectious diseases in humans, animals and plants. In the course of his life, he received many prestigious honors from institutions of learning around the world, including 22 honorary doctorates and 5 honorary professorships, for his ground-breaking work in the discovery and development of new medicines, which either saved the lives of millions of people or substantially improved the quality of their lives.

 
It is altogether exceptional for a scientist to receive so many accolades from around the world for abilities in so many different disciplines. For example, he was awarded honorary doctorates in medicine, the natural sciences, veterinary medicine, science in general and even philosophy. On the other hand, it is not so astonishing if it is considered that he combined within himself all the characteristics of a chemist, a pharmacologist and a medical doctor. His multi-faceted and broad insight into drug research exerted a positive influence on the general research climate in the company for forty years. His personal philosophy of life was fully consistent with his many-sided personality and open-mindedness.
 

Dr. Paul himself often compared the various scientific disciplines involved in pharmaceutical research to the fingers of a hand: “A good scientist is someone who succeeds in getting the various scientific disciplines to work together harmoniously just as the fingers of a hand can function properly only if they work in concert.” Dr. Paul achieved that goal as no one else. Each of the many honors bestowed on him in various countries in the course of his life is a token of appreciation of his life’s work.

Dr. Paul always personified a unique combination: on the one hand, the brilliant scientist, and on the other, a highly successful business leader. Notwithstanding, nothing was farther from his nature than to attribute his accomplishments exclusively to his own person. A case in point was his elevation to the peerage in 1990, which he regarded not merely as a personal honor but above all as a recognition of the merits of all those who had worked with him over the years and devoted their best efforts to establishing the excellent reputation that Janssen Pharmaceutica had acquired worldwide in only a few decades.

More than 50 years ago, to be precise in 1953, Dr. Paul, on a modest scale, started up his own chemical and pharmaceutical research activities in his parents’ company in Turnhout. From the very outset his primary goal was to develop better medicines capable of improving health and the quality of life. In 1957 the company moved to Beerse, where it grew into a pharmaceutical concern with some forty affiliates around the world. In 1961 Janssen Pharmaceutica joined the Johnson & Johnson worldwide family of companies. Within this multinational group of companies, Janssen evolved independently into an internationally reputed pharmaceutical company distinguished by the exceptional productivity of its research and its broad range of effective medicines for humans, animals and plants. The most important of these human medicines will now be briefly described.

Contributions to a Better Quality of Life
Thanks to its innovative products, of which HALDOL* and RISPERDAL are the best known, Janssen brought about a genuine revolution with reference to mental illness. Literally tens of millions of people, owing to these products, have been able to rebuild a virtually normal life. In the meantime, the search has continued for yet better medicines for not only the initially targeted illnesses but also related mental disorders.

Without the armamentarium of pain-controlling medicines discovered by Dr. Paul Janssen and his teams the history of surgery would have been radically different. Thanks to FENTANYL, developed in the 1960s, surgeons can perform long and extremely complex operations. Before FENTANYL was discovered, 2% of all patients undergoing an operation died because of the anesthetic. Owing to the discovery of Janssen’s anesthetic, this figure was brought down to 0%. Without SUFENTA, a derivative of this product, the first artificial heart implant would have been out of the question.

 

DUROGESIC patches today constitute an exceptionally user-friendly method of chronic pain control. Due to the user friendliness and long-lasting activity of these patches, many pain patients enjoy a better quality of life.

In addition, Janssen has developed medicines, like IMODIUM, that can be life-saving in the event of acute diarrhea.
 

For a number of other widespread gastrointestinal disorders, like esophageal inflammation, acid reflux and poor digestion, the company has discovered equally effective medicines, such as MOTILIUM, which is a staple of any pharmacy specialized in travel medicines. The worming agent VERMOX is a unique medicine, which is used worldwide to combat worm diseases, especially in developing countries. It is no accident this product is one of the five medicines discovered by Janssen that in the course of time was put on the World Health Organization's List of Essential Medicines.

Fungi cause annoying disorders, such as dandruff or discoloration of the toenails, but can also provoke fatal infections of the internal organs. DAKTARIN was the first product ever discovered that could cure a broad spectrum of fungal disorders. It is also used for opportunistic infections, for example in AIDS patients, who are very susceptible to fungal infections of the mouth, throat and esophagus as a result of their compromised immune system. NIZORAL and SPORANOX followed and were effective in combating both external and internal fungal infections by means of a simple treatment.

Finally, new disease areas are constantly being investigated in the search for medicines that can offer answers to the numerous challenges of public health. These include infectious diseases, cardiovascular disorders, metabolic disorders, cancer, tuberculosis, depression, and many others.
You can find more information about the election of "The Greatest Belgian" on www.degrootstebelg.be.

* The names in capital letters are Johnson & Johnson tradenames.


“It was the concern of Dr. Paul for public health in the developing countries that brought us together. His belief was unshakeable that through scientific innovation not only could we save millions of lives, but that in this way we could also help these countries overcome poverty. Moreover, he was one of the first to see that developing countries represented a real market, present and future. Just how accurate his vision turned out to be was confirmed when he, as the first person to do so, founded a western pharmaceutical company in China!”

Peter Piot
Executive Director, UNAIDS
Assistant Secretary General of the United Nations in Geneva
 

“The point of all this is that Ehrlich (1908), Domagk (1939), Bovet (1957), Hitchings, Elion and Black (1988) all got Nobel Prizes. The greatest of us all, Dr. Paul, didn’t. He was certainly nominated several times. Perhaps he did too much, so that his work couldn’t be easily summarized in a sentence or two. All I know is that his life’s work was Nobel Prize worthy. In his will, Alfred Nobel commanded that the interest from his estate should be distributed in the form of prizes to those who “shall have conferred the greatest benefit on mankind”. By any yardstick, Dr. Paul must have been a great candidate.”

Sir James Black
Nobel Prize winner for medicine, 1988

 
Press Releases
25/11/2005 Quality Manager of the Year: Ben Barbé of Janssen Pharmaceutica
24/10/2005 The Xian-Janssen Joint Venture Fetes Its 20 Years
17/10/2005 Janssen Pharmaceutica achieves Kyoto target in 2005 and switches over to green energy company-wide
13/10/2005 Johnson & Johnson starts building European Distribution Center for its Medical Devices & Diagnostics Division in Courcelles, Belgium
02/10/2005 Janssen Pharmaceutica als “vrouwvriendelijk” bedrijf
02/10/2005 Business Open Day at Janssen Pharmaceutica
29/06/2005 Annual Report 2004
20/06/2005 Opening High Containment Production Chain
08/04/2005 The Greatest Belgian
15/03/2005 The Archeological Survey of India and Janssen Pharmaceutica sign Memorandum
14/03/2005 On March 14 Johnson & Johnson inaugurated the Drug Safety Evaluation Center in Beerse.
08/03/2005 For the fifth time running, Janssen Pharmaceutica has been ranked among the Top 3 Most Attractive Employers in Belgium.
13/01/2005 Ajit Shetty, Manager of the year 2004
<< Back
 

 

 
© Janssen Pharmaceutica N.V., 1997-2010.

This site is published by Janssen Pharmaceutica NV and is intended for visitors from Europe. Use of the site constitutes your consent to application of European laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice.